Literature DB >> 15095964

Combined approach for far-lateral lumbar disc herniation.

Mehmet Faik Ozveren1, Turgay Bilge, Seref Barut, Mustafa Eras.   

Abstract

This study evaluated the combination of the classical interlaminar approach and the intertransverse route through a midline approach for the treatment of 18 patients with far-lateral lumbar disc herniations, as identified by magnetic resonance imaging. The patients presented with acute severe sciatica, antalgic posture, positive Lasègue sign and femoral stretch test, motor and sensory deficits, and reflex loss findings. Discectomy of all 18 patients was performed by the combined approach. Neurological outcome of all patients was excellent in the follow-up period, ranging from 5 to 8 years. This combined midline approach permits complete evacuation of the involved disc level and treatment of additional bone resection procedures. Therefore, we advocate this approach in far-lateral lumbar disc herniation cases.

Entities:  

Mesh:

Year:  2004        PMID: 15095964     DOI: 10.2176/nmc.44.118

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  3 in total

1.  Ultra-long-term outcome of surgically treated far-lateral, extraforaminal lumbar disc herniations: a single-center series.

Authors:  Gerhard Marquardt; Markus Bruder; Stephanie Theuss; Matthias Setzer; Volker Seifert
Journal:  Eur Spine J       Date:  2011-12-17       Impact factor: 3.134

2.  Microdecompression for extraforaminal L5-s1 disc herniation; the significance of concomitant foraminal disc herniation for postoperative leg pain.

Authors:  Dong Yeob Lee; Sang-Ho Lee
Journal:  J Korean Neurosurg Soc       Date:  2008-07-20

3.  Postural changes in women with chronic pelvic pain: a case control study.

Authors:  Mary Lls Montenegro; Elaine Cl Mateus-Vasconcelos; Júlio C Rosa E Silva; Francisco J Candido Dos Reis; Antonio A Nogueira; Omero B Poli-Neto
Journal:  BMC Musculoskelet Disord       Date:  2009-07-07       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.